Protein Regulator of Cytokinesis 1 (PRC1) is a key microtubule-associated protein essential for cytokinesis, organizing antiparallel microtubule bundles at the spindle midzone. Overexpression of PRC1 is strongly associated with poor prognosis, chemoresistance, and metastasis in multiple cancers, including hepatocellular carcinoma (HCC), breast cancer, and non-small cell lung cancer (NSCLC). This makes PRC1 a highly attractive oncology target for small-molecule inhibitors, protein-protein interaction (PPI) disruptors, and PROTAC-mediated degradation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PRC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRC1 Recombinant Protein (Full-Length & Truncated Domains) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for PPI and microtubule-binding assays. |
View PRC1 Products |
| Gene Delivery | PRC1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to study mitotic arrest and target engagement. |
View PRC1 Products |
| Benchmark Ab | Anti-PRC1 Recombinant Antibody Recombinant positive control for Western Blot, Immunofluorescence, and IHC. |
View PRC1 Products |
| Validator | PRC1 siRNA Set For knockdown verification and phenotypic rescue assays. |
View PRC1 Products |
| Related Target A | KIF4A Direct binding partner of PRC1; key motor protein regulating midzone microtubule dynamics. |
View KIF4A Products |
| Related Target B | PLK1 Polo-like kinase 1 phosphorylates PRC1 to regulate its spatial distribution during cytokinesis. |
View PLK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Microtubule-bundling interference | High-purity, structurally intact recombinant PRC1 proteins (>95% by SDS-PAGE) ensuring native binding capacity. |
| PPI screening (PRC1-KIF4A / PRC1-PLK1) | Truncated domain proteins (e.g., KIF4A-binding domain of PRC1) strictly verified by mass spectrometry. |
| Lack of Controls | Recombinant Benchmark Antibodies available for target confirmation in cell-based assays. |
| False Positives in Phenotypic Screening | Sequence-verified siRNA pools included for target-specific validation. |
Live PRC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of PRC1 is rapidly evolving. Historically labeled as "undruggable" due to its intracellular localization and scaffolding nature, the focus has shifted from traditional occupancy-driven small molecules to proximity-induced modalities. The next wave of R&D is heavily focused on PROTACs (Proteolysis Targeting Chimeras) and peptide-mimetic disruptors targeting the PRC1-KIF4A or PRC1-PLK1 interfaces, aiming to selectively induce mitotic catastrophe in rapidly dividing tumor cells while sparing normal tissue.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Academic Institutes, Biotech Startups | Hepatocellular Carcinoma (HCC), Breast Cancer | Degradation kinetics assays (Need lentivirus for stable reporter cell line construction) |
| Small Molecule (PPI Inhibitor) | Oncology-focused Biopharma | NSCLC, Ovarian Cancer | In vitro binding assays (Need high-purity recombinant PRC1 and KIF4A proteins) |
| Peptide Therapeutics | Translational Medicine Consortiums | Refractory Solid Tumors | Target engagement validation (Need validated siRNA and benchmark antibodies) |